FEGO Biotech

FEGO Biotech is a Singapore-based biotechnology company specializing in the development of advanced drug delivery systems using red blood cell-derived extracellular vesicles (RBCEVs). The company's proprietary FEGO (Functional Exosome-based Gene-delivery and Organ-targeting) platform enables the precise delivery of therapeutic cargoes, such as mRNA, siRNA, and antisense oligonucleotides, to specific organs and tissues. By leveraging the natural properties of red blood cells, FEGO Biotech can produce exosomes at a significantly larger scale and lower cost compared to traditional cell-culture methods. This technology aims to overcome common delivery barriers, including immunogenicity and limited tissue penetration, which often hinder the efficacy of gene therapies. The company is currently advancing a pipeline focused on oncology, including treatments for acute myeloid leukemia, and rare diseases. Their approach seeks to provide safer and more effective treatments by ensuring therapeutic agents reach their intended cellular targets with high efficiency.